DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT00974272

CompletedPhase 4

Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

39

actual

Study population

Dyslipidemia, Prediabetes / glucose intolerance, Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Triglycerides, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00974272
Org study IDPR-015

Timeline

Milestones

Study first posted2009-09-10estimated
Last update posted2009-09-10estimated
Study start2006-08 (month precision)
Primary completion2008-11actual (month precision)
Study completion2008-11actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

DyslipidemiaPrediabetes / glucose intoleranceType 2 diabetes

Eligibility

Who can enroll

Minimum age35 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Recently diagnosed type 2 diabetes (within 3 years) on diet or IGT
•Fasting triglyceride levels >140 and < 400 mg/dl and values varying less than 35% between two screening measurements
•Normal liver function tests and white blood cell count

Exclusion criteria

•Type 2 Diabetes for > 3 years or HbA1c ≥ 7.5
•Known or suspected Type 1 Diabetes
•Any diabetes medications in the past 3 weeks, TZD in the prior 3 months or prior regular use of insulin
•Creatinine > 2.0 mg/dl or other evidence of active kidney disease
•Hepatic enzyme elevation > 2x normal
•Known Nonalcoholic Fatty Liver Disease
•Malabsorption of fat or other nutrients, severe lactose intolerance or other significant gastrointestinal or pancreatic problems
•Recent history of nausea or vomiting
•Acute bacterial or viral illness or evidence of other active infection in the past 4 weeks
•A prior cardiovascular event, stable or unstable angina or other major illness in the past 6 months
•Current regular use of anti-inflammatory medications or antioxidants, including over the counter medications and high dose salicylates (>1 g/day)
•Any lipid lowering therapy in the prior 3 weeks other than a statin medication. Subjects receiving a statin medication must be on a stable dose for at least 2 months prior to participation.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Cardiometabolic biomarkers

2 endpoints
Primary/protocol endpoint

Triglyceride concentration in serum

Time frame:Before and up to 8-hours post-injection

Triglycerides, change

descriptive, improvement

LOINC 2571-8

Secondary/protocol endpoint/low confidence

serum or plasma lipoproteins, apolipoproteins and inflammatory markers; endothelial function

Time frame:Before and up to 8 hours post-injection

descriptive

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.